According to The Cancer Genetic Atlas (TCGA) and DepMap databases, RGS19 has been reported to be overexpressed in numerous cancers, particularly in bladder and ovarian cancers, where RGS19 can achieve unrestricted cell proliferation by enhancing AKT signalling and cell cycle control of the immune system. This evidence concerns the gene RGS19 and cancer.